Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.
暂无分享,去创建一个
E. Kimby | M. Ghielmini | H. Hawle | S. Rondeau | B. Østenstad | H. Bersvendsen | P. de Nully Brown | E. Zucca | M. Bargetzi | A. Ferreri | H. Hagberg | S. Dirnhofer | A. Lohri | U. Novak | S. Hayoz | D. Rauch | A. Vanazzi | U. Mey | B. Wahlin | F. Hitz | M. Hernberg | A. Johansson | T. Zander | W. Mingrone | F. Krasniqi | S. Berardi Vilei
[1] J. Gribben,et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Chloé B. Steen,et al. Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] G. Salles,et al. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma , 2018, The New England journal of medicine.
[4] P. Barr. Counterpoint: Can Chemotherapy Be Eliminated in the Treatment of Follicular Lymphoma? , 2018, Oncology.
[5] E. Kimby,et al. Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] J. Leonard,et al. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). , 2017 .
[7] W. Klapper,et al. Obinutuzumab for the First‐Line Treatment of Follicular Lymphoma , 2017, The New England journal of medicine.
[8] E. Kimby,et al. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Armitage,et al. Is watch and wait still acceptable for patients with low-grade follicular lymphoma? , 2016, Blood.
[10] M. Ghielmini,et al. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] A. López-Guillermo,et al. Life expectancy of young adults with follicular lymphoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] J. Gribben,et al. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Czuczman,et al. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] E. Kimby,et al. Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas , 2015, Leukemia & lymphoma.
[15] J. Cerhan,et al. Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] Michael L. Wang,et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. , 2014, The Lancet. Oncology.
[17] R. Gascoyne,et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Ghielmini,et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] E. Kimby,et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study , 2014, Leukemia.
[20] J. Tuscano,et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non‐Hodgkin lymphoma , 2014, British journal of haematology.
[21] R. Stephens,et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. , 2014, The Lancet. Oncology.
[22] Summer S. Han,et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. , 2013, Blood.
[23] M. Stauch,et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.
[24] K. Yeow,et al. Diagnosis and treatment of follicular lymphoma. , 2011, Swiss medical weekly.
[25] Andrew Lister,et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial , 2011, The Lancet.
[26] M. Ghielmini,et al. Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03 , 2010, Blood.
[27] M. Ghielmini,et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] R. Gascoyne,et al. Prognostic factors in follicular lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] F. Cavalli,et al. Patterns of survival of follicular lymphomas at a single institution through three decades , 2010, Leukemia & lymphoma.
[30] R. Marcus,et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] George Muller,et al. Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells , 2008, Clinical Cancer Research.
[32] E. Kimby,et al. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group , 2008, Leukemia & lymphoma.
[33] M. Czuczman,et al. Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab in vivo , 2007, British journal of haematology.
[34] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] W. Hiddemann,et al. Clinical Trials and Observations , 2005 .
[36] Max Wolf,et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. , 2006, Blood.
[37] Boris Freidlin,et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] M. Ghielmini,et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. , 2004, Blood.
[39] K. Maclennan,et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial , 2003, The Lancet.
[40] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Daniel J Sargent,et al. Optimising the design of phase II oncology trials: the importance of randomisation. , 2009, European journal of cancer.